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Cell dosage is a limiting factor for cord blood transplantation
(CBT), especially for adult patients. Most CB banks practice red
cell depletion (RCD) techniques to save storage space, which incur
signiﬁcant nucleated cell loss after processing. One method to
maximize cell recovery and still reduce volume after processing is
to deplete plasma (PD), but not the red blood cells. Not washing
UCB (NW) after thawing also minimizes cell loss. A third strategy
is to employ double cords. A large racially diverse PD UCB
inventory of over 25,000 units is now available. An audited retro-
spective analysis was performed on all adult patients with malig-
nancies that have available engraftment and/or survival data, with
20 AML, 18 ALL, 12 CML, and 18 patients transplanted for other
malignant indications. Of these, 20 patients had standard risks
(29%), 34 patients (50%) with advanced risks and 14 risk status
unknown (21%). Patients were classiﬁed as adults in two different
ways: by age (16 years and older) and by weight (at least 50kg). By
age, there were 55 patients transplanted with 67 PD UCB units (27
double cords). By weight, there were 62 patients transplanted with
75 PD UCB units (31 double cords). The median age of patients of
the combined group was 29 years old (range 9.6-59); median
weight 62 kg (range 39-112); male 55%. Transplant characteristics
indicated a median # HLA ABDR matches of 4.0; median pre-
freeze TNC dose 2.9  107/kg; median post-thaw TNC dose as
reported by TC 2.5 107/kg; median pre-freeze CD34 dose 0.9
105/kg; transplants outside of U.S. 24%; double unit transplant
47%; non-myeloablative 29%. Fifty-two percent of the trans-
planted UCB were washed post-thaw (W) and 41% were infused
without post-thaw wash (NW), with 7% of the units without
available post-thaw data. Median follow-up time was 111.5 days
(range 2-1263 days). Kaplan-Meier estimates were used for en-
graftment, relapse, TRM, OS and Relapse Free Survival (RFS)
rates with all patients who expired before engraftment counted as
engraftment failures. Patients 16 years or older were also stratiﬁed
by risk status. Results are summarized below. These results dem-
onstrate that HSCT using unrelated PD UCB can be performed
safely and effectively in adult patients with malignancies.
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Hematopoietic stem cells (HSC) interact with stromal cells, os-
teoblasts and matrix proteins in the hematopoietic niche. This
interaction plays an important role in HSC trafﬁcking, prolifera-
tion and differentiation. Signiﬁcant data support the roles of both
the SDF-1/CXCR4 and the VCAM1-VLA-4 axes in stem cell
homing and mobilization. Little is known regarding the impact of
these ligand-receptor pairs in leukemia cell trafﬁcking. We hy-
pothesize that both CXCR4VLA-4 play important roles in leu-
kemia cell trafﬁcking while also transmitting protective signals
enhancing survival and resistance to chemotherapy and that their
blockade may enhance the sensitivity of AML to chemotherapy.
To evaluate this we developed a model of human APL in which
the PML-RAR
 is “knocked-into” the mouse cathepsin G locus
allowing for expression in the promyelocyte compartment. APL
tumors generated from these CGPR/ mice were transduced with
retroviral contructs containing the Click Beetle Red/eGFP optical
imaging reporter gene for tracking APL cells using biolumines-
cence imaging (BLI). Unlike other AML cell lines tested these
APL cells rapidly migrated to the BM (femurs and spine) by day4
followed by egress to the spleen (11) then to the peripheral blood
and death (18-22). The administration of AMD3100, a CXCR4
antagonist, induced a rapid mobilization of normal HSC and leu-
kemia cells from the BM into peripheral blood (PB). The addition
of AMD3100 1 hour before and 3 hours after either ara-C or
daunorubicin on day 11 resulted in signiﬁcant improvement in
overall survival and decrease in total photon emission compared to
those mice treated with chemotherapy alone.
We have extended these studies using an inhibitor of VLA-4
(AMD15057) and have shown that this molecule directly mobilizes
HSC and APL cells from the BM into the peripheral blood within
minutes and when administered with AMD3100 has a synergistic
effect on both HSC and APL mobilization. Current studies are
aimed at looking at in vitro and in vivo effects of blocking CXCR4
and VLA-4 axes on normal HSC and leukemia cell mobilization
and what effects these events might have on the sensitivity of
normal and leukemic stem cells to chemotherapy and other geno-
toxic stresses.
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MRD based on leukemia-speciﬁc immunoglobulin (Ig) and
T-cell receptor (TCR) gene rearrangements has become a tool
inﬂuencing clinical decisions in many therapeutic trials for
childhood acute lymphoblastic leukemia (ALL). It has been
repeatedly documented, that positive MRD pre-transplant is
highly predictive for post-transplant relapse of ALL, but we
have failed to document the same value in 14 children with
PhALL which at our unit underwent allogeneic stem cell
transplantation (SCT). The presence of BCR/ABL fusion gene
offers a possibility of the fusion transcript detection - a faster
and cheaper alternative to Ig/TCR-based MRD monitoring. Up
to now, no direct comparison based on a sufﬁcient number of
samples has been done. We have analyzed 350 follow-up sam-
ples from 16 children (aged 4-17 years) with BCR/ABL-positive
ALL by Ig/TCR-based RQ-PCR and by RT-RQ-PCR for
BCR/ABL transcripts. All children expressed m-BCR/ABL
transcript at the time of diagnosis; 3 of 16 children expressed
both m-BCR/ABL and M-BCR/ABL transcripts representing
the p190 and p210 variant of BCR/ABL protein, respectively.
For further analysis we used the higher value of m- and M-BCR/
ABL as the BCR/ABL MRD level. For the comparison with
Ig/TCR-based method, MRD levels in follow-up samples were
related to the expression levels in diagnostic samples, which
were set to 1. In total, 133 (38%) and 127 (36%) samples were
negative and positive by both methods, respectively. The quan-
titative levels differed by more than 1 log in 46 (36%) double-
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positive samples, being underestimated by Ig/TCR method in
25 cases and by m-BCR/ABL quantiﬁcation in 21 cases. We
found signiﬁcantly more false-negative samples by Ig/TCR ap-
proach (70 samples) compared to BCR/ABL quantiﬁcation (20
samples). Altogether, we tested 219 bone marrow (BM), 130
peripheral blood (PB) and 1 cerebrospinal ﬂuid samples. The PB
samples showed signiﬁcantly worse correlation between the two
methods compared to BM (p0.02). In our hands, the quanti-
ﬁcation of BCR/ABL transcripts appears to be a more reliable
method than the generally accepted Ig/TCR-based MRD mon-
itoring as the number of false-negative samples by BCR/ABL
quantiﬁcation is signiﬁcantly lower. This contention is sup-
ported by outcome of our patients who subsequently underwent
allogeneic SCT. In this group BCR/ABL positivity preceding
allogeneic SCT seems to represent a better predictor of subse-
quent relapse than Ig/TCR approach.
Supported by VZ MZO 00064203.
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FLUDARABINE AND TREOSULFAN; A NOVEL REDUCED-TOXICITY REG-
IMEN WITH EFFECTIVE ANTI-LEUKEMIA ACTIVITY IN PATIENTS WITH
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Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive treatment for patients (pts) with AML and MDS. However, it
may be associated with signiﬁcant toxicity. New regimens are
continuously explored trying to reduce toxicity while retaining
anti-leukemia effect. Treosulfan is a prodrug of a bifunctional
alkylating cytotoxic agent used in the past for the treatment of
ovarian cancer. In-vitro it mediates cytotoxicity against cell lines of
a variety of hematological malignancies including acute leukemia.
In escalated doses it shows myeloablative as well as immunosup-
pressive properties. Initial studies in SCT showed promising re-
sults with relatively limited extramedullary toxicity. In the current
study we explored a regimen of ﬂudarabine (total dose 150 mg/m2)
and treosulfan (12 gr/m2  3) in pts with AML and MDS not
eligible for standard SCT. The study included 24 pts, 15 male, 9
female. The median age was 55 years (range, 30-69). Nineteen had
AML (8 secondary, 5 to MDS, 1 to myeloﬁbrosis, 1 to breast
cancer, 1 to NHL), 5 had MDS. Two pts had a prior autologous
SCT (1 for NHL and 1 for AML). All pts had chemo-sensitive or
untreated disease at the time of SCT; 11 pts were in CR1, 5 in
CR2/3, 6 previously untreated and 2 in untreated relapse. The
donor was an HLA matched sibling (n11) or matched unrelated
(n13). Twenty-one pts engrafted, one later rejected the graft.
Three pts died prior to engraftment. The median time to ANC
0.5  109/ L and platelet 20  109 / L was 15 days (range, 11-21)
and 16 days (range, 11-50), respectively. With a median follow-up
of 12 months (range, 1-27), 16 pts are alive in CR, one of them in
CR 4 months following treatment for post SCT relapse. Eight pts
died (relapse-2, organ toxicity – 2, sepsis - 2, CNS bleeding - 1,
graft rejection - 1). The cumulative incidence of acute and chronic
GVHD was 20% and 41%, respectively. The estimated 1-year
overall and disease-free survival were 66% (95% CI, 11-43) and
63% (95% CI, 11-42), respectively. The cumulative incidence of
relapse at 1- year after SCT is 11% (95% CI, 3-41) and the
cumulative incidence of non-relapse mortality at 1 year is 26%
(95% CI, 13-52). In conclusion, the combination of ﬂudarabine
and treosulfan is relatively safe, with effective anti-leukemia po-
tential, in pts not eligible for myeloablative conditioning. This
regimen merits further study in larger scale studies.
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Relapse of acute myeloid leukemia (AML) following myeloabla-
tive allogeneic stem cell transplantation portends a dismal prog-
nosis. Therapy aimed at enhancing graft-versus-leukemia (GVL)
effect, e.g., by donor leukocyte infusion, has limited success in
AML, and a second ablative transplant is associated with prohibi-
tive mortality in adults. From April 2001 to March 2006, nine
patients, ranging in age from 21 to 57, with high risk myeloid
malignancy (7 AML and 2 advanced myelodysplasia) and overt
bone marrow relapse less than one year after ablative busulfan/
cyclophosphamide conditioning have been treated with a cytore-
ductive regimen of ﬂudarabine (30 mg/m2/day) and cytarabine
(2g/m2/day) for 5 days (-7 through -3) and G-CSF administration
(5 ug/kg daily starting day -8) with or without idarubicin (8 mg/m2
days -7, -5, and -3) (8 cases) or ﬂudarabine 30 mg/m2 for 3 days
and 200 cGy total body irradiation (1 case). G-CSF mobilized
peripheral blood stem cells from their original HLA-matched
donor (8 siblings, 1 unrelated) were infused. Graft versus host
disease (GVHD) prophylaxis was mycophenolate mofetil for 30
days and cyclosporine with a rapid taper. The mean onset of
relapse after the initial ablative transplant was day 172 (range
106-271). Fludarabine-based therapy was well tolerated with no
treatment related mortality. Full donor chimerism was established
by day 72 (range 26-113) in 6 patients (67%). Five patients died: 2
from relapse without GVHD at day 30 and 301 after RIST
(one patient with complex and one with Ph cytogenetic abnor-
malities), 3 from relapse with evidence of GVHD. Four patients
survive: one has relapsed at 91 days after RIST and is receiving
alternate therapy, while three patients (30%) survive in complete
remission at 100, 635 and 1795 days after salvage RIST. In 5
cases (56%), the duration of complete remission after RIST was
longer than after the initial ablative transplant. We conclude that
ﬂudarabine-based RIST is a safe and effective salvage therapy
offering a chance for increased survival with low morbidity in
patients relapsing after ablative transplant. In addition, RIST ther-
apy has resulted in long-term disease free survival in over 20% of
cases in this study.
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Pts with ﬂudarabine-refractory CLL have a poor prognosis with
conventional therapies with median survival of 12 months. We
previously reported 2-year overall survival of 60% for 64 pts
treated with nonablative HCT from related (n44) or unrelated
(n20) donors (Sorror et al. JCO 2005, 23: 3819). Here, we
present an update on the ﬁrst 64 pts (median of 48 [range: 24-86]
months) and report data on 18 additional pts transplanted between
February 2004 and January 2006. The 82 pts were given nonabla-
tive HCT from related (n52) or unrelated donors (n30). Me-
dian pt age was 55.5 (range 42-72) years, and the median number
of prior regimens was 4 (range 1-12). Seventy-nine pts were re-
fractory to at least 1 regimen, 72 to ﬂudarabine (FLU), 27 to
alkylating agents, 23 to rituxumab, 7 to CAMPATH®, and 3 had
failed high-dose autologous HCT. Thirty-six pts (44%) had dis-
ease responsive to the last chemotherapy [36% partial (PR) and 7%
complete remission (CR)] while 37 were resistant and 9 had un-
tested relapse. Conditioning for HCT consisted of 2 Gy TBI alone
(n13) or combined with FLU (n69), 90 mg/m2. All pts received
G-PBMC. The incidences of grades II, III, and IV acute GVHD
were 40%, 16%, and 2% respectively, and chronic extensive
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